Considering recent efforts to establish a biological definition of Alzheimer's disease (AD) within the context of the amyloid/tau/neurodegeneration (ATN) framework,2 the identification of reliable, cost‐effective, non‐invasive biomarkers capable of detecting early signs of the disease is a crucial goal. This evidence concerns the gene MAPT and Alzheimer disease.